BTAI's logo.
Ticker Symbol: BTAI

BioXcel Therapeutics Inc

$27.66 - 14-07-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001720893

Company Profile

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 555 Long Wharf Dr
CEO: Vimal Mehta
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing


Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $2.43
Change: -$0.16 ( -6.18%)
Days Range: $2.41 - $2.62
Beta: 1.70
52wk. High: $34.13
52wk. Low: $2.23
Ytd. Change -94.12%
50 Day Moving Average: $3.04
200 Day Moving Average: $12.38
Shares Outstanding: 29270000


Market Cap: 7.1B
PE Ratio: -0.34
EPS (TTM): -7.13


Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A